DOP2015000004A - Indolecarbonitrilos como moduladores selectivos receptores de androgeno - Google Patents

Indolecarbonitrilos como moduladores selectivos receptores de androgeno

Info

Publication number
DOP2015000004A
DOP2015000004A DO2015000004A DO2015000004A DOP2015000004A DO P2015000004 A DOP2015000004 A DO P2015000004A DO 2015000004 A DO2015000004 A DO 2015000004A DO 2015000004 A DO2015000004 A DO 2015000004A DO P2015000004 A DOP2015000004 A DO P2015000004A
Authority
DO
Dominican Republic
Prior art keywords
indolecarbonitrilos
androgen receptors
selective modulators
modulators
selective
Prior art date
Application number
DO2015000004A
Other languages
English (en)
Spanish (es)
Inventor
Philip Stewart Turnbull
Rodolfo Cadilla
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49117887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2015000004(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of DOP2015000004A publication Critical patent/DOP2015000004A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
DO2015000004A 2012-07-17 2015-01-08 Indolecarbonitrilos como moduladores selectivos receptores de androgeno DOP2015000004A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261672455P 2012-07-17 2012-07-17
US201361748874P 2013-01-04 2013-01-04

Publications (1)

Publication Number Publication Date
DOP2015000004A true DOP2015000004A (es) 2015-03-15

Family

ID=49117887

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2015000004A DOP2015000004A (es) 2012-07-17 2015-01-08 Indolecarbonitrilos como moduladores selectivos receptores de androgeno

Country Status (39)

Country Link
US (5) US8957104B2 (enExample)
EP (1) EP2875013B1 (enExample)
JP (1) JP6106746B2 (enExample)
KR (1) KR102127939B1 (enExample)
CN (1) CN104619693B (enExample)
AR (1) AR091770A1 (enExample)
AU (1) AU2013291721B2 (enExample)
BR (1) BR112015000940B1 (enExample)
CA (1) CA2879104C (enExample)
CL (1) CL2015000119A1 (enExample)
CO (1) CO7240378A2 (enExample)
CR (1) CR20150008A (enExample)
CY (1) CY1120064T1 (enExample)
DK (1) DK2875013T3 (enExample)
DO (1) DOP2015000004A (enExample)
EA (1) EA026371B8 (enExample)
ES (1) ES2657912T3 (enExample)
HR (1) HRP20180061T1 (enExample)
HU (1) HUE036238T2 (enExample)
IL (1) IL236448A (enExample)
IN (1) IN2014KN02993A (enExample)
JO (1) JO3384B1 (enExample)
LT (1) LT2875013T (enExample)
ME (1) ME02996B (enExample)
MX (1) MX349943B (enExample)
MY (2) MY198512A (enExample)
NZ (1) NZ703129A (enExample)
PE (1) PE20150371A1 (enExample)
PH (1) PH12015500104B1 (enExample)
PL (1) PL2875013T3 (enExample)
PT (1) PT2875013T (enExample)
RS (1) RS56810B1 (enExample)
SG (1) SG11201408493WA (enExample)
SI (1) SI2875013T1 (enExample)
SM (1) SMT201800115T1 (enExample)
TW (1) TWI574946B (enExample)
UY (1) UY34911A (enExample)
WO (1) WO2014013309A1 (enExample)
ZA (1) ZA201500096B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10155099B2 (en) 2009-09-21 2018-12-18 Cook Regentec Llc Method for infusing stem cells
MY198512A (en) 2012-07-17 2023-09-01 Glaxosmithkline Ip No 2 Ltd Indolecarbonitriles as selective androgen receptor modulators
US9902694B2 (en) 2014-01-21 2018-02-27 GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED Crystalline forms
KR20190077607A (ko) * 2014-10-16 2019-07-03 지티엑스, 인코포레이티드 Sarm을 이용하는 비뇨기 장애의 치료 방법
CN105130872B (zh) * 2015-08-25 2018-01-30 江西师范大学 一种3位三氟甲基取代吲哚的制备方法
CN110437125B (zh) * 2019-09-06 2021-03-12 苏州旺山旺水生物医药有限公司 一种Tezacaftor中间体II的制备方法
WO2022204235A1 (en) * 2021-03-23 2022-09-29 Nido Biosciences, Inc. Bicyclic compounds as androgen receptor modulators
CN115010574B (zh) * 2022-06-06 2024-01-05 爱斯特(成都)生物制药股份有限公司 1-溴-2-氯-4-氟-2碘苯的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK12742000A3 (sk) 1998-02-25 2001-05-10 Genetics Institute, Inc. Inhibítory fosfolipázových enzýmov, farmaceutický prostriedok s ich obsahom a ich použitie
AU3951899A (en) * 1998-06-19 2000-01-05 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
MXPA04011479A (es) 2002-05-24 2005-02-14 Bayer Cropscience Ag Procedimiento para la preparacion de derivados de tioalquilaminas.
CN1960973A (zh) * 2004-03-30 2007-05-09 惠氏公司 作为去甲肾上腺素(ne)与血清素(5-h t)活性和单胺重摄取的调控剂以治疗血管舒缩症状(vms)的1-(1h-吲哚-1-基)-3-(4-甲基哌嗪-1-基)-1-苯基丙烷-2-醇衍生物和相关化合物
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
CA2564953A1 (en) 2004-05-03 2005-11-24 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (sarms)
EP1771413B1 (en) 2004-05-03 2011-09-21 Janssen Pharmaceutica NV Benzofuran derivatives as selective androgen receptor modulators (sarms)
JP5070042B2 (ja) 2004-05-03 2012-11-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 選択的アンドローゲン受容体モジュレーター(sarms)としての新規インドール化合物
ES2340180T3 (es) * 2004-06-01 2010-05-31 F.Hoffmann-La Roche Ag 3-amino-1-arilpropil-indoles como inhibidores de reabsorcion de monoaminas.
EP1913000B1 (en) * 2005-07-29 2012-01-11 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
BRPI0709612A2 (pt) * 2006-03-15 2011-07-19 Wyeth Corp composto de fórmula i; método para o tratamento de um distúrbio no sistema nervoso central relacionado ou afetado pelo receptor histamina-3 em um paciente que necessita deste tratamento; método para a inibição do receptor h3; composição farmacêutica; e processo para a preparação de um composto de fórmula i
CN101426778A (zh) * 2006-03-15 2009-05-06 惠氏公司 作为组胺-3拮抗剂的n-经取代-氮杂环基胺
WO2008042571A2 (en) * 2006-09-29 2008-04-10 Smithkline Beecham Corporation Substituted indole compounds
DK2384326T3 (da) * 2008-08-20 2014-05-05 Zoetis Llc Pyrrolo[2,3-d]pyrimidinforbindelser
US9095572B2 (en) 2009-01-09 2015-08-04 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2010118287A1 (en) * 2009-04-10 2010-10-14 Radius Health, Inc. Selective androgen receptor modulators
KR20120083452A (ko) * 2009-10-15 2012-07-25 화이자 인코포레이티드 피롤로[2,3-d]피리미딘 화합물
JP5739446B2 (ja) * 2009-12-18 2015-06-24 ファイザー・インク ピロロ[2,3−d]ピリミジン化合物
EP2665707B1 (en) * 2011-01-20 2017-01-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
BR112014014325B1 (pt) * 2011-12-21 2022-06-07 Jiangsu Hengrui Medicine Co.,Ltd. Derivados de pirrol do tipo anel heteroarílico de seis membros, seus usos e seus processos de preparação, e composição farmacêutica
MY198512A (en) 2012-07-17 2023-09-01 Glaxosmithkline Ip No 2 Ltd Indolecarbonitriles as selective androgen receptor modulators
US9902694B2 (en) * 2014-01-21 2018-02-27 GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED Crystalline forms

Also Published As

Publication number Publication date
CA2879104C (en) 2020-08-25
NZ703129A (en) 2017-06-30
TW201416349A (zh) 2014-05-01
ME02996B (me) 2018-10-20
HK1208867A1 (en) 2016-03-18
KR102127939B1 (ko) 2020-06-29
PT2875013T (pt) 2018-02-28
MX349943B (es) 2017-08-21
CN104619693A (zh) 2015-05-13
AR091770A1 (es) 2015-02-25
MY198512A (en) 2023-09-01
MX2015000825A (es) 2015-07-17
US20150080449A1 (en) 2015-03-19
AU2013291721B2 (en) 2016-02-25
JO3384B1 (ar) 2019-03-13
SG11201408493WA (en) 2015-02-27
TWI574946B (zh) 2017-03-21
RS56810B1 (sr) 2018-04-30
PH12015500104A1 (en) 2015-03-02
DK2875013T3 (en) 2018-01-22
ES2657912T3 (es) 2018-03-07
US20140024694A1 (en) 2014-01-23
PE20150371A1 (es) 2015-03-27
CO7240378A2 (es) 2015-04-17
EP2875013A1 (en) 2015-05-27
JP6106746B2 (ja) 2017-04-05
US20200270210A1 (en) 2020-08-27
LT2875013T (lt) 2018-02-26
US11299457B2 (en) 2022-04-12
HRP20180061T1 (hr) 2018-02-23
HUE036238T2 (hu) 2018-06-28
IN2014KN02993A (enExample) 2015-05-08
EP2875013B1 (en) 2017-11-29
CY1120064T1 (el) 2018-12-12
WO2014013309A1 (en) 2014-01-23
IL236448A0 (en) 2015-02-26
EA201492237A1 (ru) 2015-06-30
US20190127326A1 (en) 2019-05-02
PH12015500104B1 (en) 2015-03-02
US10710963B2 (en) 2020-07-14
US20170073309A1 (en) 2017-03-16
US9533948B2 (en) 2017-01-03
CA2879104A1 (en) 2014-01-23
CN104619693B (zh) 2019-08-13
SMT201800115T1 (it) 2018-03-08
SI2875013T1 (en) 2018-03-30
PL2875013T3 (pl) 2018-06-29
EA026371B8 (ru) 2017-06-30
AU2013291721A1 (en) 2015-02-26
IL236448A (en) 2016-10-31
US10196353B2 (en) 2019-02-05
UY34911A (es) 2014-02-28
EA026371B1 (ru) 2017-03-31
MY173845A (en) 2020-02-24
CR20150008A (es) 2015-03-09
BR112015000940B1 (pt) 2022-05-17
JP2015522603A (ja) 2015-08-06
ZA201500096B (en) 2017-07-26
BR112015000940A2 (pt) 2017-06-27
KR20150032333A (ko) 2015-03-25
CL2015000119A1 (es) 2015-04-24
US8957104B2 (en) 2015-02-17

Similar Documents

Publication Publication Date Title
DOP2015000004A (es) Indolecarbonitrilos como moduladores selectivos receptores de androgeno
IL274003A (en) T cell receptors recognizing mhc class ii-restricted mage-a3
CO2018006982A2 (es) Agonista triple de receptores de glucagón/glp-1/gip
ES2930298T3 (es) Moduladores del receptor de glucocorticoides de azadecalina condensada con heteroaril-cetona
DK3406609T3 (da) Bicykliske aza-forbindelser som muskariniske receptoragonister
EA201891209A1 (ru) Модуляторы хемокиновых рецепторов
BR112014019331A2 (pt) anticorpos para cd47 e métodos de uso desses
DK3440105T3 (da) T-cellereceptorer
ES2529890T8 (es) Agentes para el tratamiento de trastornos que implican la modulación de los receptores rianodina
EA201791310A1 (ru) Химерные антигенные рецепторы к bcma
CL2014003572A1 (es) Compuestos derivados de aril-sultamo o una sal del mismo, como moduladores de la funcion del receptor de orfano rorc; composicion que los contiene; y su uso para el tratamiento o la profilaxis de la artritis.
UA109931C2 (xx) Піримідинциклогексильні модулятори глюкокортикоїдних рецепторів
GT201300196A (es) Moduladores del receptor de glucagón
DK3024468T3 (da) T-cellereceptorer
CR20140479A (es) Moduladores del receptor del estrogeno y sus usos
EP2970281A4 (en) SUBSTITUTED BENZOL COMPOUNDS
DK3087071T3 (da) Tricykliske forbindelser som anticancermidler
CR20140440A (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
CO6910195A2 (es) Moduladores selectivos del receptor andrógeno
CL2016002240A1 (es) Derivados de piperidina como antagonista de receptores de orexina
DK3145916T3 (da) Imidazolderivater som formylpeptidreceptormodulatorer
MX372922B (es) Un derivado de la cromona como el antagonista del receptor de la dopamina d3 para su uso en el tratamiento del trastorno del espectro autista.
EP3375066C0 (en) EMERGENCY POWER SUPPLY FOR LIGHTING DEVICES
UY34646A (es) Compuestos de espirohidantoína y su uso como moduladores selectivos del receptor de andrógenos
BR112014027843A2 (pt) análogos de hexa-depsipeptídeo como compostos anticancerígenos